CEO Modig Berndt Sells 2,292 Shares of Pharvaris NV Amid Strong Valuation

Insider Selling on a High‑Growth Stage Company

Pharvaris NV, a clinical‑stage biopharmaceutical company specializing in oral B₂ receptor antagonists, recently executed a routine insider sale under its 10‑b‑5 plan. On 13 July 2026, Chief Executive Officer Modig Berndt sold 2,292 shares of the company’s common stock at an average price of €34.97 per share. This transaction, while modest relative to Pharvaris’s €2.1 billion market capitalization, aligns with a broader pattern of disciplined disposals that have maintained Modig’s equity position at approximately 135 k shares over the preceding two months.

Regulatory and Market Context

The sale occurred while the share price hovered above the 52‑week high, suggesting that the CEO is taking advantage of a peak‑valuation window. The transaction is fully compliant with the company’s pre‑established 10‑b‑5 plan, a statutory framework designed to prevent market manipulation and ensure transparency. No regulatory filings indicate that this sale deviates from the routine, structured schedule of insider transactions.

Implications for Investors

Insider activity of this nature—small, planned, and executed under a 10‑b‑5 plan—typically signals confidence in a company’s long‑term prospects. Investors should view the current transaction as a routine “cash‑in” that is unlikely to erode shareholder value. Nevertheless, cumulative insider sales over a short period can serve as a subtle bearish cue, especially if subsequent clinical milestones fail to materialise. The current bullish sentiment, reflected in a market‑wide buzz score of +10 and moderate social‑media intensity (≈11 %), indicates that the market has not yet overreacted to the sale. Continued monitoring of the next filing cycle will be prudent.

Modig Berndt’s Transaction Profile

Over the past three months, Modig has sold roughly 6,000 shares in total, averaging €30–35 per share. The sales are evenly split between a few large blocks and numerous smaller trades, all executed under a 10‑b‑5 plan. This disciplined approach indicates that Modig’s primary objective is liquidity management rather than market manipulation. The CEO’s holdings remain substantial (≈135 k shares), reflecting a long‑term ownership stake that aligns with the company’s growth trajectory. Historically, Modig’s trades have not correlated with negative performance announcements, reinforcing the view that he is maintaining a balanced ownership profile.

Strategic Outlook for Pharvaris

Pharvaris’s pipeline is centered on oral B₂ receptor antagonists, with several candidates advancing through pre‑clinical and early‑clinical stages. The company’s market cap has risen 51 % year‑to‑date, although its negative price‑earnings ratio remains typical for a firm still in the development phase. Recent quarterly results demonstrate incremental progress but have yet to generate revenue. Insider selling at a high valuation may provide the company with breathing room to fund late‑stage trials without resorting to new capital markets exposure. For investors, the key will be the next data release from the clinical program and any shifts in executive ownership that could signal a change in confidence.

Bottom Line

The current CEO sale is a small, planned move that fits within Modig’s regular 10‑b‑5 plan and does not materially alter the share price or ownership concentration. It reflects a prudent liquidity strategy against a backdrop of positive market sentiment and a robust, albeit early‑stage, product pipeline. Investors should continue to track clinical milestones and subsequent insider filings to gauge whether the company maintains its upward trajectory.